JP6355711B2 - ヘモグロビンの修飾のための化合物及びその使用 - Google Patents

ヘモグロビンの修飾のための化合物及びその使用 Download PDF

Info

Publication number
JP6355711B2
JP6355711B2 JP2016501052A JP2016501052A JP6355711B2 JP 6355711 B2 JP6355711 B2 JP 6355711B2 JP 2016501052 A JP2016501052 A JP 2016501052A JP 2016501052 A JP2016501052 A JP 2016501052A JP 6355711 B2 JP6355711 B2 JP 6355711B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
cycloalkyl
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016501052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514131A5 (https=
JP2016514131A (ja
Inventor
アール． ハリス，ジェイソン
アール． ハリス，ジェイソン
ダブリュー． メトカルフ，ブライアン
ダブリュー． メトカルフ，ブライアン
リ，チェ
ザ セカンド，ステファン エル． グワルトニー
ザ セカンド，ステファン エル． グワルトニー
Original Assignee
グローバル ブラッド セラピューティクス インコーポレイテッド
グローバル ブラッド セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/815,810 external-priority patent/US20140274961A1/en
Priority claimed from US14/010,455 external-priority patent/US20150057251A1/en
Application filed by グローバル ブラッド セラピューティクス インコーポレイテッド, グローバル ブラッド セラピューティクス インコーポレイテッド filed Critical グローバル ブラッド セラピューティクス インコーポレイテッド
Publication of JP2016514131A publication Critical patent/JP2016514131A/ja
Publication of JP2016514131A5 publication Critical patent/JP2016514131A5/ja
Application granted granted Critical
Publication of JP6355711B2 publication Critical patent/JP6355711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2016501052A 2013-03-15 2014-03-10 ヘモグロビンの修飾のための化合物及びその使用 Active JP6355711B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/815,810 2013-03-15
US13/815,810 US20140274961A1 (en) 2013-03-15 2013-03-15 Compounds and uses thereof for the modulation of hemoglobin
US14/010,455 2013-08-26
US14/010,455 US20150057251A1 (en) 2013-08-26 2013-08-26 Compounds and uses thereof for the modulation of hemoglobin
PCT/US2014/022742 WO2014150261A1 (en) 2013-03-15 2014-03-10 Compounds and uses thereof for the modulaton of hemoglobin

Publications (3)

Publication Number Publication Date
JP2016514131A JP2016514131A (ja) 2016-05-19
JP2016514131A5 JP2016514131A5 (https=) 2017-04-13
JP6355711B2 true JP6355711B2 (ja) 2018-07-11

Family

ID=51580730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501052A Active JP6355711B2 (ja) 2013-03-15 2014-03-10 ヘモグロビンの修飾のための化合物及びその使用

Country Status (6)

Country Link
EP (1) EP2970184B1 (https=)
JP (1) JP6355711B2 (https=)
CA (1) CA2902874C (https=)
ES (1) ES2710380T3 (https=)
TW (1) TWI630201B (https=)
WO (1) WO2014150261A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2643403T3 (es) 2011-12-28 2017-11-22 Global Blood Therapeutics, Inc. Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MX379235B (es) 2013-03-15 2025-03-11 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina.
WO2014150258A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN114181195A (zh) 2014-02-07 2022-03-15 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
SG11201804647TA (en) 2015-12-04 2018-06-28 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
EP3472150A1 (en) 2016-06-17 2019-04-24 Fronthera U.S. Pharmaceuticals LLC Hemoglobin modifier compounds and uses thereof
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
CN113365992B (zh) * 2018-12-21 2024-05-28 晶体制药独资有限公司 用于沃塞洛托的制备的方法和中间体
US12434217B2 (en) 2019-09-12 2025-10-07 Asymchem Laboratories (Fuxin) Co., Ltd. Device for continuously preparing 2,6-dihydroxybenzaldehyde

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1193786B (it) * 1980-12-18 1988-08-24 Wellcome Found Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione
CA2370245A1 (en) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
CA2507545C (en) * 2002-12-04 2011-06-21 Virginia Commonwealth University Use of furfural derivatives as anti-sickling agents
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
CN1875002B (zh) * 2003-11-05 2011-08-03 霍夫曼-拉罗奇有限公司 作为ppar激动剂的苯基衍生物
TWI407960B (zh) * 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
AR073304A1 (es) * 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
ES2643403T3 (es) * 2011-12-28 2017-11-22 Global Blood Therapeutics, Inc. Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular

Also Published As

Publication number Publication date
ES2710380T3 (es) 2019-04-24
EP2970184B1 (en) 2018-12-05
TW201520204A (zh) 2015-06-01
EP2970184A4 (en) 2016-10-26
CA2902874A1 (en) 2014-09-25
JP2016514131A (ja) 2016-05-19
TWI630201B (zh) 2018-07-21
CA2902874C (en) 2021-04-20
EP2970184A1 (en) 2016-01-20
WO2014150261A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
JP6355711B2 (ja) ヘモグロビンの修飾のための化合物及びその使用
US20160024127A1 (en) Compounds and uses thereof for the modulation of hemoglobin
US20190010176A1 (en) Compounds and uses thereof for the modulation of hemoglobin
JP6401771B2 (ja) ヘモグロビンの修飾のための化合物及びその使用
US9604999B2 (en) Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) Compounds and uses thereof for the modulation of hemoglobin
US9776960B2 (en) Compounds and uses thereof for the modulation of hemoglobin
US20100048957A1 (en) Method to prepare pure curcumin
JP2018502098A5 (https=)
JP2007520452A (ja) ホスホネート誘導体としてのイノシン一リン酸デヒドロゲナーゼインヒビター
EP2366691B1 (en) The nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof
WO2019122084A1 (en) Process for the preparation of nicotinamide riboside chloride derivatives
US20080306028A1 (en) Erianin Salts, Their Preparation Methods and Pharmaceutical Compositions Containing the Same
KR20210038562A (ko) 젬시타빈의 인-함유 프로드러그
US20170029452A1 (en) Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof
CN108602825A (zh) 具有抗癌活性的嘌呤化合物
EP3237015B1 (fr) Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
US20240425515A1 (en) Compound of the 7a,8,9,10,11,11a-hexahydro-1h,7h-pyrano[2,3-c]xanthene type, method of preparation thereof, intermediates thereof and therapeutic applications thereof
JP2016530293A (ja) イソオキサゾール化合物のジアステレオ選択的合成方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180612

R150 Certificate of patent or registration of utility model

Ref document number: 6355711

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250